US Officials: Global Crises Require Accelerated Drug Evaluation
This article was originally published in Scrip
With the world experiencing three major health crises in the past decade – severe acute respiratory syndrome, H1N1 pandemic influenza and Ebola – and the potential for other emerging diseases to turn into an epidemic, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), there's a critical need for the rapid evaluation of experimental therapies, US officials said, laying out their argument in an Aug. 5 Perspectives article in the New England Journal of Medicine.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.